| Project/Area Number |
23592017
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Fukushima Medical University |
|---|
Principal Investigator |
SHIMURA Tatsuo 福島県立医科大学, 医学部, 准教授 (00282393)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SHIBATA Masahiko 福島県立医科大学, 医学部, 教授 (10226178)
TAKENOSHITA Seiichi 福島県立医科大学, 医学部, 教授 (10167489)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | galectin-3 / 膵癌 / ＡＭＦ / AMF / IPMC / galectin |
|---|
| Research Abstract |
Galectin-3 (Gal-3) is beta-galactoside-binding protein, having binding capacity with glycoprotein and glycolipid on a cell surface. Gal-3 engages in cell differentiation, organ formation, tumor progression, apoptosis and so on, however, precise mechanisms of them have not yet been clarified.
We investigated the relationship between Gal-3 and pancreatic cancer, especially on cell proliferation, migration and invasion using pancreatic cancer cell lines. We also analyzed changes of tolerance toward anti-cancer drugs when expression level of Gal-3 was inhibited in the cell lines. Inhibition of Gal-3 expression led to inhibition of migration and invasion of the cells. It also augmented their susceptibility to anti-cancer agents, like gemcitabine and cisplatinum.
|
